Teva Pharma targets R&D, other areas in plan to trim $2B

Teva Pharmaceutical Industries ($TEVA) CEO Jeremy Levin today gave Wall Street an early picture of what the company will look like going forward and it showed it having a much slimmer profile. He said it will cut up to $2 billion in costs over the next 5 years as it remakes itself into something more than just a generic drug manufacturer. Yet in the process of beefing up its capacity to bring novel therapies to market, the drugmaker wants to finds some of its savings from R&D cost-chopping. Article



Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.